Protein kinase CK2 (casein kinase II) is a serinethreonine protein kinase with many substrates, some of which are involved in cell cycle regulation. CK2 activity is elevated in human solid tumors and leukemia, and dysregulated expression of CK2 induces lymphoma in transgenic mice. Mice that are de®cient in p53 also develop lymphomas, and p53 activity may be regulated by CK2 phosphorylation. Here we demonstrate that CK2a transgenic mice partially or completely de®cient in p53 develop thymic lymphomas at a markedly accelerated rate when compared to p53-de®cient mice lacking the transgene. Lymphomas originating from CK2a transgenic mice that are heterozygous for p53 generally lose the wild type p53 allele, indicating that loss of p53 is an important step in tumor progression. Moreover, though lymphomas occur as early as 3 weeks of age in the transgenic mice that are nullizygous for p53, they are still monoclonal, indicating that additional stochastic mutations are required for their development. These lymphomas express high levels of myc mRNA and frequently ectopically express Lmo-2, a transcription factor involved in human T cell acute lymphocytic leukemia. The p53-null CK2a transgenic lymphomas grow rapidly but are highly prone to apoptosis, suggesting that transformation occurs through synergistic dysregulation of cell cycle control induced by misexpression of CK2 and loss of function of p53.
Introduction
Protein kinase CK2 (also known as casein kinase II) is a tetrameric serine-threonine protein kinase composed of two a catalytic subunits (a or a') and two b regulatory subunits. CK2 is present in all eukaryotic organisms, is ubiquitously expressed, and is highly conserved in evolution, indicating a vital cellular role for this protein (Allende and Allende, 1995) . CK2 phosphorylates proteins on serines or threonines that are in an acidic environment, the simplest consensus sequence being S/TXXE/D (Hrubey and Roach, 1990; Litch®eld et al., 1990; Marin et al., 1992; Meggio et al., 1991; Perich et al., 1992) . Targets of CK2 include enzymes involved in DNA, RNA, and protein synthesis; transcription factors; signal transduction mediators; cytoskeletal and structural proteins; and other nuclear and nucleolar factors (Pinna, 1990) .
CK2 activity is elevated in embryonic tissues as well as in human cancer cells including leukemias and solid tumors (Daya-Makin et al., 1994; Faust et al., 1996; Friedrich and Ingram, 1989; Gapany et al., 1995; Issinger, 1993; Mestres et al., 1994; Munstermann et al., 1990) . This elevated activity in rapidly dividing cells suggests an important role for CK2 in the regulation of cellular proliferation, and we have directly demonstrated its critical role in the pathogenesis of cancer by over-expressing the a catalytic subunit in lymphocytes of transgenic mice (Seldin and Leder, 1995) . CK2a transgenic mice develop lymphoma beginning at about 6 months of age with an incidence of 15 ± 20% per year. The latency of onset of disease and the clonality of the lymphomas indicate that other mutations are required in a multistep process of lymphocyte transformation. As phosphorylation of myc and max by CK2 favors DNA binding of activating heterodimeric myc/max complexes in vitro (Berberich and Cole, 1992) , we hypothesized that co-expression of the CK2a transgene and a c-myc transgene might be synergistic in vivo. In fact germ-line acquisition of both of these oncogenic transgenes results in neonatal leukemia, suggesting that dysregulation of these genes can be sucient to transform lymphoid cells (Seldin and Leder, 1995) . Another helix ± loop ± helix transcription factor that is phosphorylated by CK2 is Tal-1. Tal-1 heterodimerizes with Lmo proteins to form complexes that regulate transcription in early erythroid and myeloid cells and are essential for their development (Foroni et al., 1992; Warren et al., 1994) . TAL-1 is frequently rearranged or ectopically expressed in human T-ALL (Hwang and Baer, 1995) , and expression of a Tal-1 transgene leads to lymphoid malignancy in mice that is accelerated by the presence of a CK2a transgene (Kelliher et al., 1996) .
The sequence speci®c DNA binding activity of the tumor suppressor p53 is regulated by CK2 (Hupp et al., 1992) . p53 is a nuclear transcription factor with a short half-life (reviewed in Levine, 1997) . In response to genotoxic DNA damage, p53 accumulates and causes either a G1 cell cycle arrest associated with the induction of the cyclin-dependent kinase inhibitor p21, or apoptosis associated with the induction of death genes such as bax or the recently identi®ed PAG608 (el-Deiry et al., 1993; Israeli et al., 1997; Miyashita and Reed, 1995; Yin et al., 1997) . p53 may also play a role in the maintenance of diploid ®delity and in DNA repair (Bakalkin et al., 1994; Cross et al., 1995; Fukasawa et al., 1996; Lee et al., 1995; Oberosler et al., 1993) . The function of p53 as a tumor suppressor gene was ®rst illuminated in studies of families with the Li ± Fraumeni cancer susceptibility syndrome. Individuals that inherit a single mutant allele of p53 are highly susceptible to tumor development in association with loss of the remaining wild type allele (Malkin et al., 1990; Srivastava et al., 1990) . In addition to this rare inherited cancer susceptibility syndrome, over 50% of sporadic human tumors carry mutations in the p53 gene suggesting that loss of functional p53 protein may be one of the most prevalent steps in human tumorigenesis (Hollstein et al., 1994) .
The role of p53 mutation in tumorigenesis has been validated through examination of mice in which the wild type p53 allele was replaced with a null allele through homologous recombination (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994) . Mice that inherit one null p53 allele, recapitulating the genetics of the familial Li ± Fraumeni syndrome, develop a variety of tumors at a year or more of age. Mice that are homozygous for the null p53 allele (nullizygous) are mostly viable and develop lymphomas and sarcomas at a few months of age. This is in contrast to mice that are nullizygous for many other tumor suppressor genes such as Rb or brca 1 which die during embryonic development (Lee et al., 1992; Ludwig et al., 1997) . It may be the case that the recently described p73 (Jost et al., 1997; Kaghad et al., 1997; Schmale and Bamberger, 1997) , which shares some homology with p53, may replace some of the function of p53 in development. However, a minority of nullizygous p53 mice do die in utero with defects of the neural tube (Sah et al., 1995) . It is not understood what epigenetic or stochastic events during development determine which embryos will form normally and which will be defective.
The occurrence of tumors in p53-de®cient mice can be accelerated by the over-expression of oncogenes. Well-expressed myc transgenes accelerate lymphomagenesis in p53 heterozygous mice (Hsu et al., 1995; Elson et al., 1995) , while a weak myc transgene accelerates lymphomagenesis in p53 nullizygous mice but not in heterozygotes (Blyth et al., 1995) . Mammary tumors in p53-de®cient mice are accelerated by Wnt-1 (Jones et al., 1997) but not by myc (Elson et al., 1995) , and salivary tumors are accelerated by ras (Hundley et al., 1997) . Because of the biochemical interaction of CK2 and p53 and the important role of both in the regulation of lymphocyte proliferation, we hypothesized that dysregulation of CK2 might also collaborate with loss of p53 to aect lymphocyte development or transformation. To test this, we mated transgenic mice overexpressing CK2a with p53 de®cient mice. While development of the lymphoid organs appears normal, lymphoma is dramatically accelerated in proportion to the reduction in p53 levels.
Results

Normal lymphoid organogenesis in mice transgenic for CK2a and de®cient in p53
To assess the cooperativity between CK2 dysregulation and p53 loss, FVB mice overexpressing CK2a in the lymphoid compartment (Seldin and Leder, 1995) were crossed with p53 de®cient mice (Donehower et al., 1992) . The CK2a transgene and p53 null alleles were inherited in the F1 ospring in a Mendelian fashion, segregating independently into mice carrying or lacking the CK2a transgene, and wild type (p53 +/+ ) or heterozygous for the p53 null allele (p53
). F1 mice were intercrossed to produce F2 mice completely lacking a functional p53 allele (p53
) with or without the CK2a transgene. Viable mice from all genotypes had a normal appearance and normal lymphoid organs at weaning age. In the F2 generation, the p53 7/7 genotype appeared at a frequency of 14.7% (14/95), instead of the expected 25%. However, when we genotyped embryonic day 12 and day 13 embryos, 27.5% (8/29) of the embryos analysed were p53 7/7 , indicating that a developmental defect results in loss of some p53 7/7 embryos during gestation. This observation of partial embryonic lethality in the FVB strain background is consistent with previous reports of p53 7/7 embryogenesis in the 129Sv background, in which 16.6% of viable ospring from intercrosses were of the p53 7/7 genotype . The defective 129Sv embryos frequently had abnormalities in neural tube formation (Sah et al., 1995) , and we have seen similar features in our FVB p53 7/7 embryos (not shown).
The rate of tumor formation is accelerated in transgenic CK2a mice in proportion to the decrease in functional p53 gene dosage
The p53
+/7 and p53 7/7 mice with or without the CK2a transgene were observed for the development of tumors. Tumor incidence was compared to that of FVB mice transgenic for CK2a and wild type for p53 (Seldin and Leder, 1995) , which develop clonal T cell lymphomas with a 50% incidence (t 1/2 ) at 400 days of age (n=133, Figure 1 ). p53 +/7 mice that are nontransgenic for CK2a have a similar incidence of Figure 1 Kaplan ± Meier survival plot of CK2a transgenic and p53 de®cient mice. The survival curve shown for CK2a transgenic mice is derived from previous studies (Seldin and Leder, 1995 and the p53 7/7 curves is small but statistically signi®cant by logrank test (P50.05), and the lymphoma incidence was 100% versus 43% in the two respective populations tumorigenesis, with 50% of the mice developing disease by 454 days. Although only a small number of mice were observed for this length of time (n=13), the kinetics are similar to that reported in heterozygous p53 +/7 mice in other genetic backgrounds (Donehower et al., 1992 Jacks et al., 1994) . Both lymphomas and solid tumors were identi®ed in these mice. Mice carrying the CK2a transgene that were heterozygous for the p53 null allele (CK
) showed a pronounced acceleration of tumorigenesis: such mice began to develop tumors as early as 69 days and 50% were diseased by 175 days (n=71, Figure 1 ). These tumors were exclusively lymphomas.
As reported in other genetic backgrounds, tumor development was quite rapid in mice lacking any functional p53 gene (p53
), beginning at 60 days in our colony. 50% of these mice developed tumors by 77 days, and all developed tumors by 186 days (n=14). mice also developed small hemangiomas, but lymphoma was the major cause of morbidity and mortality. Fifty percent of the CK + p53
7/7 mice developed tumors by 69 days. Although the t 1/2 was only 9 days less than the t 11/2 for the p53 7/7 mice, a log-rank test for comparison of survival curves (Matthews and Farewell, 1996) indicated that the dierence between these two survival curves was statistically signi®cant (P50.05). Moreover, many of the p53 7/7 mice with sarcomas were sacri®ced for pathologic studies and +/7 mouse with a thymic lymphoma, the thymus is diusely replaced with malignant lymphocytes, eacing the normal architecture (660). (c) At higher power, large lymphoblastic cells are seen. In some areas, small dark pyknotic cells, evidence of high apoptotic activity, can be seen (61000). (d) While these lymphomas usually originate in the thymus, they rapidly become metastatic and frequently invade visceral organs. Here, lymphoma cells in®ltrating the kidney can be seen (6500) Protein kinase CK2a misexpression and p53 loss in lymphoma E Landesman-Bollag et al might have survived considerably longer, as these tumors were not very aggressive.
Lymphoma histology and immunophenotype
CK2a transgenic, p53 de®cient mice that became ill had a hunched appearance and were dyspneic, usually without external evidence of tumor or adenopathy. Upon necropsy, massive thymic enlargement was found, frequently accompanied by splenomegaly and pallor of visceral organs. Histological analysis of the tissues revealed lymphoma in all of these mice. These lymphomas were characterized by replacement of the thymus with a diuse in®ltrate of large lymphoblastic cells, with pleiomorphic nuclei containing pale chromatin and prominent nucleoli. Sections of these lymphomas exhibited frequent mitoses but also numerous pyknotic cells. In most of the mice, the cells from the thymoma in®ltrated into other organs including spleen, lymph nodes, liver and kidneys ( Figure 2 mice were examined by¯ow cytometry to determine their lineage of origin. All of the lymphomas were of T cell immunophenotype, expressing CD3 and a/b T cell receptors. Two of these lymphomas also expressed the B220 isoform of CD45, which is typically expressed on cells of the B lineage, but none of them expressed surface immunoglobulin. The dierentiation state of these lymphomas was determined by analysis of T cell surface markers. The developmental stages of cells in a normal thymus can be seen in Figure 3b , where the earliest prothymocytes lack CD4 and CD8 (`double negative' cells, lower left quadrant), then acquire both CD4 and CD8 ( + double positive cells ( Figure 3c ) and ®ve Figure 3 The immunophenotype of the lymphomas was determined by¯ow cytometric analyses using antibodies directed against CD4, biotinylated and bound to streptavidin-PE (red¯uorescence, FL2, ordinate) and CD8 coupled to FITC (green¯uorescence, FL1, abscissa Growth behavior of CK2a transgenic, p53 de®cient lymphomas As described above, CK2a transgenic, p53 de®cient mice that developed lymphomas rapidly progressed to respiratory failure caused by massive enlargement of the thymus within the closed thoracic space. This aggressive clinical behavior was re¯ected by the highly proliferative behavior of the lymphoma cells. Upon subcutaneous transplantation into syngeneic hosts, 10 6 cells formed palpable masses in as little as 7 ± 10 days. While T cell lymphomas are often dicult to establish in tissue culture ex-vivo, frequently requiring the addition of exogenous T cell growth factors such as interleukin-2, the CK2a transgenic, p53-de®cient lymphomas were easily adapted to cell culture, where they grew vigorously. Cell cycle analysis by propidium iodide (PI) staining for DNA content of freshly obtained lymphoma cells or of lymphoma cells in culture showed that an unusually high proportion of the cells in these lymphomas were actively cycling. For comparison, in a typical thymus (in which T cells are rapidly dierentiating and proliferating) about 5% of the cells are in cycle (summing the S+G 2 /M cells, Figure 4a ). In the CK + p53 +/7 lymphomas, typically 40 ± 60% of the viable cells are in cycle at any time (Figure 4b and c) .
Although the CK
lymphoma cells grew rapidly in vivo and ex vivo, pyknotic cells were common in histological sections of these lymphomas (Figure 2c) , and a proportion of the cells in culture appeared to constantly be undergoing chromatin condensation and cell death. The cell cycle analyses indicated that 30 ± 40% of the cells from both the fresh lymphomas and the culture-adapted cell lines contain a hypodiploid DNA content, appearing as an extra peak to the left of the G 0 /G 1 peak in the PI histogram (Figure 4b and c) . The apoptotic nature of these dying cells was demonstrated by the presence of the characteristic pattern of DNA degradation with internucleosomal laddering (not shown). This apoptotic behavior was maintained throughout months of passage in cell culture and occurred without any speci®c induction, but could be minimized by daily passage of the cells. As will be discussed below, these lymphomas appear to lack any functional p53. Thus, the ongoing apoptosis process is p53-independent.
CK2a transgenic, p53 de®cient-derived lymphomas are clonal and exhibit`loss of heterozygosity'
T cell receptor gene rearrangements were examined to determine whether the lymphoma derived from a single transformed cell or many cells. Southern blots of HindIII-digested DNA from lymphomas appearing in both CK + p53 +/7 and CK + p53 7/7 mice hybridized with a TCR J b 2B probe revealed novel rearranged bands ( Figure 5 ). Some lymphomas retain one germline band, while others appear to have undergone rearrangement of both alleles. The appearance of the new bands indicates clonality of these lymphomas. If the transformation process was polyclonal, no single predominant TCR rearrangement would be detected. +/7 mice, eight (72%) were found to no longer contain the wild type allele (seven of these are shown in Figure 6 ). To see whether the three lymphomas that retained a structurally normal p53 allele at the DNA level were able to express p53 mRNA transcripts. RNA samples from these lymphomas were analysed by Northern blot. None of these showed a detectable p53 transcript, which could be seen in the control thymus (data not shown). Thus, loss of p53 does appear to be necessary for transformation of these lymphocytes, occuring through`loss of heterozygosity' in the majority of cases, in which the wild type allele is either deleted or converted to the null allele, or through mutations resulting in loss of stable mRNA transcripts.
Additional mutations in CK2a transgenic, p53 de®cient-derived tumors
The loss of the wild type p53 allele or mRNA in the CK + p53 +/7 lymphomas and the rapidity of lymphomagenesis in the CK + p53 7/7 mice suggest that complete inactivation of p53 is critical for lymphoma formation. However, even in the CK + p53
7/7 mice, the lymphomas are still clonal. This suggests that a further random event is required for lymphomagenesis in addition to the three molecular defects present in all of the lymphocytes of such mice (gain of function of CK2a and loss of function of two p53 alleles). To identify additional mutations that might be responsible for the`fourth hit' in the CK + p53 7/7 mice, we examined the expression of several oncogenes that are dysregulated in transgenic mouse models of T cell acute lymphoblastic leukemia.
Chromosomal translocations involving a T cell receptor locus leading to aberrant expression of transcriptional regulators such as MYC, LMO-1, LMO-2, TAL-1, or HOX-11 are characteristic of human T cell acute lymphoblastic leukemia (T-ALL) (Hwang and Baer, 1995; Shivdasani and Orkin, 1996) . Transgenic mouse models of T-ALL (Seldin, 1995) have been generated by overexpressing these candidate oncogenes in the T cell compartment, and CK2 has been shown to cooperate with misexpression of Tal-1 lymphocyte transformation. We hybridized Northern blots of lymphoma RNAs with probes for c-myc, Tal-1, Hox-11 and Lmo-2. All lymphomas exhibited levels of c-myc above the wild type thymus RNA control in the Northern analysis, but Tal-1 and Hox-11 did not show any detectable message in any of the lymphomas (data not shown). Lmo-2 expression was detected in three of eight lymphomas but not in the other ®ve, or in normal thymus, by Northern analysis (data not shown). Upon reverse transcription and PCR amplification of lymphoma ®rst strand cDNA with Lmo-2 primers, an additional four lymphomas exhibited expression of Lmo-2 (Figure 7) . A thymus originating from an apparently healthy CK + p53 +/7 mouse also expressed high levels of Lmo-2 (Figure 7 , lane 4, # 6809), as did a lymphoma from a CK2 transgenic mouse with no p53 de®ciency (Figure 7 , lane 14 # 6808). As expected, Lmo-2 was expressed well in wild type brain and spleen, but expression was not detected in thymus under these conditions (lane 1 ± 3).
Discussion
These experiments establish that dysregulated expression of protein kinase CK2, through transgenic overexpression of the catalytic a subunit, synergizes with progressive loss of p53 to accelerate the development of lymphoma in mice. CK2 upregulation has been seen in a number of human tumors, and p53 loss or mutation is one of the most common molecular abnormalities in human cancer. We ®rst began to look at the interaction of these two defects by generating mice that bear the CK2a transgene and are hetero- +/7 mice. DNA was extracted from the fresh lymphomas and the wild type and/or null p53 alleles were ampli®ed by PCR with appropriate primers and electrophoresed on 1% agarose gels (left lane and right lane of each lymphoma, respectively). The null allele is ampli®ed as a 390 bp product and the wild type allele is ampli®ed as a 760 bp product. As can be seen, DNA from the ®rst four lymphoma specimens contained only the null allele, consistent with loss of the wild type allele or gene conversion to the null allele, indicative of`loss of heterozygosity'. The wild type allele has been retained in DNA from the last three specimens. DNA prepared from tail samples from all of these mice ampli®ed both the wild type and null alleles ). Mice that are heterozygous for the p53 null allele (without the CK2a transgene) recapitulate the genetics of patients with Li ± Fraumeni syndrome and develop tumors with a t 1/2 of 454 days. Mice that carried the CK2a transgene developed T cell lymphoma with a t 1/2 of 400 days. Mice bearing both of these genetic abnormalities developed lymphoma with a t 1/2 of 175 days. This dramatic acceleration is consistent with two models. In the ®rst, CK2 overexpression might indirectly inhibit the function of the residual p53 protein in the heterozygous or haploinsucient mice, interfering with a critical`guardian' role in the cell and causing the cell to behave as if it has little or no functional p53. In the second model, the overexpressed CK2 and the p53 de®ciency might aect separate pathways of cellular growth or death control leading to a complementary and synergistic eect.
In favor of the former model, it has been shown that p53 is a target of CK2 phosphorylation (Herrmann et al., 1991; Meek et al., 1990) . The phosphorylation by CK2 of the C terminal domain of p53 induces site speci®c DNA binding of p53 in vitro (Hupp et al., 1992) ; however, the eect of phosphorylation of p53 on its growth suppressor activity and transactivation function is controversial (Fiscella et al., 1994; Hall et al., 1996; Milne et al., 1992; Rolley and Milner, 1994) . Nevertheless, CK2 and p53 associate in vivo via binding of the b subunit of CK2 to the C terminal domain of p53 (Appel et al., 1995; Filhol et al., 1992) and this association may be perturbed in our transgenic CK2a mice. Both binding of CK2 to p53 and phosphorylation of p53 by CK2 have an inhibitory eect on the p53-mediated renaturation of ssDNA (Filhol et al., 1996) , a function that may play an important role in p53 DNA repair activity and in p53 inhibition of DNA unwinding (Bakalkin et al., 1994 (Bakalkin et al., , 1995 Oberosler et al., 1993) . Such inhibition might create an environment favoring the accumulation of additional DNA mutations in our CK + p53 +/7 mice. Favoring the model that CK2 and p53 may be regulating distinct but synergistic growth pathways in cells is the fact that both are pleiotropic proteins. p53 has multiple activities that may not be all phosphorylation-dependent. CK2 has more than a hundred known substrates, many of which are potentially important regulators of cell replication.
How might we distinguish between direct and indirect cooperativity of CK2 and p53? One approach would be to demonstrate a biochemical alteration in the residual p53 caused by the transgenic expression of CK2a. Given the low-level expression of p53 in these heterozygous de®cient cells, the complex phosphorylation of p53, and the lack of a direct biological assay of its activity, we have not attempted to do this. Instead, we chose to examine the eect of the CK2a transgene in lymphocytes that are completely de®cient in p53, using mice that are nullizygous (p53
7/7
). These studies showed a statistically signi®cant decrease in survival in p53 7/7 mice expressing the CK2a transgene compared with those that do not. Furthermore, the tumor spectrum was shifted from a mix of thymomas and sarcomas to the uniform occurrence of aggressive thymomas in the transgenic and p53 null mice. This provides biological proof that the downstream mediators of the oncogenic eect of dysregulated CK2 must involve other targets than the p53 protein alone. In fact, the T cell lymphomas that arise in the CK
mice are clonal (as demonstrated by examination of V b TCR gene rearrangements), indicating that just the presence of the transgene and the complete loss of p53 are not sucient to transform all of the animal's T cells. Additional stochastic events must be required in a transformation pathway involving these genes. On the other hand, while loss of all p53 activity is not sucient to transform lymphocytes in cooperation with CK2 dysregulation, it does seem to be required or at least selected for. All of the lymphomas we analysed originating in CK + p53 +/7 mice underwent either`loss of heterozygosity' (loss of the wild type p53 allele) or mutation resulting in an untranscribed or unstable p53 mRNA transcript. By analogy, tumors arising in patients with the Li ± Fraumeni syndrome will require not only the somatic loss of the wild type p53 allele, but at least one and perhaps more than one additional mutations. Clues to the molecular nature of these mutations may be provided in the studies of ectopic and dysregulated gene expression in our mice.
What are the additional molecular events required in addition to dysregulation of CK2 and the sequential loss of both p53 alleles? Two transcriptional regulatory systems that can contribute to lymphocyte transformation have been identi®ed as candidates in these studies. Both are important contributors to human lymphoid malignancies and pathogenic in transgenic mouse models, alone and in combination with CK2. The ®rst involves the basic helix ± loop ± helix (bHLH) transcription factor c-myc. CK2 phosphorylates both myc and its DNA binding partner, max (Bousset et al., 1993) . Phosphorylation by CK2 inhibits DNA binding by max/max homodimers but does not aect DNA binding by myc/max heterodimers, favoring gene transcription (Berberich and Cole, 1992 (6808) and lane 15 (Lmo-2 only) is an ampli®cation of genomic DNA from the same mouse to verify that the endogenous gene is not ampli®ed with these primers expression of CK2a and of myc together forms a complete transformation pathway for lymphocytes, leading to the development of primitive lymphocytic leukemia in utero (Seldin and Leder, 1995) . In all of the p53 lymphomas analysed, both in the presence and absence of the CK2a transgene, we found elevated levels of myc mRNA transcript. This reiterates the importance of myc dysregulation in lymphoma.
The cooperativity of myc dysregulation and p53 loss has been demonstrated in transgenic model systems. A strong myc transgene led to lymphoma in 50% of transgenic mice with a t 1/2 of about 90 days; combined with heterozygous de®ciency of p53, the t 1/2 was reduced to about 50 days (Hsu et al., 1995) . A weaker myc transgene did not accelerate lymphomagenesis at all in p53 heterozygous mice, but reduced the t 1/2 in p53 nullizygous mice from 150 to 75 days (Blyth et al., 1995) . An MMTV-myc transgene markedly reduced the t 1/2 of lymphoma in p53 heterozygous mice to about 100 days, but an eect upon the rate of lymphomagenesis in the p53 nullizygous background could not be demonstrated (Elson et al., 1995) . Given the modest expression of the CK2a transgene in our mice (Seldin and Leder, 1995) , CK2a may in fact be as`potent' as myc in cooperating with p53 de®ciency.
The second candidate system is the TAL/LMO heterodimeric transcriptional regulators. Lmo-2 is a zinc ®nger transcription factor with an essential function in erythropoiesis (Foroni et al., 1992; Warren et al., 1994) . Lmo-2 has been recently shown to associate as a bridging molecule in a DNA binding complex with GATA-1, E47, TAL-1 and LDB1/NLI that acts as a transcriptional transactivator in erythroid cells (Wadman et al., 1997) . Ectopic expression of LMO-2, either occuring in human T cell acute lymphocytic leukemia (T-ALL) through translocation events involving juxtaposition of LMO-2 with the TCR a/d or TCR b loci or in transgenic mouse models that overexpress LMO-2 in the lymphoid compartment, leads to thymic lymphomas (Boehm et al., 1991; Fisch et al., 1992; Larson et al., 1994; Neale et al., 1995; Royer-Pokora et al., 1991) . It has recently been shown that Lmo-2 is ectopically expressed in all cases of T cell lymphoma arising in mice that are de®cient in the DNA repair gene msh-2 (Lowsky et al., 1997) . In our lymphomas, Lmo-2 expression appears to occur frequently (seven of nine), but not as universally as in the msh-2 null mice. In the same study, 40% of the lymphomas also expressed the Tal-1 bHLH transcription factor, but in our lymphomas, we were unable to detect expression of Tal-1 (not shown). Previous experiments have shown synergy between CK2a transgenics and Tal-1 transgenics (Kelliher et al., 1996) and between Tal-1 transgenics and p53 de®ciency (Condorelli et al., 1996) , but clearly Tal-1 overexpression is not essential for T cell transformation. We predict that there would be dramatic synergy between the CK2a transgene and an Lmo-2 transgene.
One of the models proposed for the role of the loss of p53 in tumors has been that the major eect of such loss is abrogation of the ability of the cell to undergo apoptosis. In our system, this is clearly not the case: T lymphoma cells lacking any functional p53 are perfectly able and in fact highly susceptible to undergoing apoptosis. Thus, p53 loss in these lymphomas leads to loss of cell cycle control (either directly, or indirectly as a consequence of genomic instability). The apoptosis seen histologically in the lymphomas and demonstrated by propidium iodide staining and DNA ladder analysis must occur through pathways that are independent of p53. This observation has also been made in mammary tumors arising in Wnt-1 transgenic, p53 null mice (Jones et al., 1997) , in salivary gland tumors induced by ras transgenic, p53 null mice (Hundley et al., 1997) and in p53 null T lymphoma cells in vitro (Strasser et al., 1994) . As CK2a misexpression in a variety of transgenic and transfected lymphocytes also aects proliferation rather than apoptosis (Seldin and Ju, unpublished) , the synergy of CK2 dysregulation and p53 loss appears to be through cooperative eects upon cell cycle regulation.
Materials and methods
Animals
The p53 null allele (Donehower et al., 1992; Harvey et al., 1993) has been bred for more than ten generations into the FVB mouse strain to eliminate the in¯uence of strain variation on the rate of tumor formation and tumor type. Mice transgenic for CK2a (from the line TG.CKA) (Seldin and Leder, 1995) (non-transgenic, p53 heterozygous null); or p53 7/7 (nontransgenic, p53 nullizygous). Mice were maintained in a speci®c pathogen-free environment inside a two-way barrier at the Boston University School of Medicine Core Transgenic Mouse Facility in accordance with the regulations of the American Association for the Accreditation of Laboratory Animal Care.
Histology
Mice were examined twice weekly for signs of tumor development. Ill-appearing mice or controls were sacri®ced and tumors and organs were collected for histopathology and other analyses. For histopathology, portions of tissues were ®xed in Optimal ®x (American Histology Reagent Company, Inc.) and processed in the Transgenic Core Pathology Laboratory at the University of California, Davis. Tissue sections were prepared and stained with hematoxylin and eosin for interpretation.
Tumor cell transplantation and culture
For transplantation, tumors were dispersed into single cell suspensions and approximately 10 6 cells were injected subcutaneously under the¯ank skin of syngeneic recipients. For tissue culture, dispersed cells were resuspended in RPMI 1640 supplemented with 10% fetal bovine serum, 4 mM glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin (Mediatech Inc. Cellgro, Herndon, VA), and 50 mm 2-mercaptoethanol (American Bioanalytical, Natick, MA) and grown in a 5% CO 2 incubator at 378C.
Immunophenotyping
Single cell suspensions were prepared from tissues. Contaminating red cells were lysed in hypotonic buer and the remaining cells were washed two times in ice cold 2% HBSS. 10 5 cells were stained with antibodies and subjected to¯ow cytometry. Antibodies to B220, CD3, CD4 and CD8 (Pharmingen, San Diego, CA) were used at 1:100 dilution in 2% HBSS containing 2% heat inactivated normal rabbit serum. Cells were incubated in 50 ml of a biotin-conjugated ®rst antibody on ice for 40 min, washed two times with 2% HBSS, resuspended in 50 ml of streptavidin-phycoerythrin (PE) and¯uorescein isothiocyanate (FITC)-conjugated second antibody, incubated on ice for 40 min and washed again with 2% HBSS. Cells were analysed in a¯ow cytometer with CellQuest software (Becton Dickinson, Mountain View, CA). Cells stained with an isotype-matched antibody or medium alone were used as negative controls and cells obtained from normal thymus were used as positive controls.
Cell cycle analysis
Propidium iodide staining was used to quantitate the DNA content of cells. 10 5 dispersed cells were resuspended in a hypotonic solution containing 50 mg/ml propidium iodide (Sigma, St Louis, MO) and 1 mg/ml sodium citrate and incubated at room temperature for 5 ± 15 min. The stained cells were analysed in a¯ow cytometer using CellQuest software. Cells containing the diploid quantity of DNA were identi®ed in the G 0 /G 1 peak. Cells with more than the diploid amount, in S phase and G 2 /M, were summed to determine the number of cells in cycle. Cells with less than the diploid amount of DNA (hypodiploid) were quantitated.
DNA and RNA analyses
DNA was extracted from tumors or 1 cm tail samples by digestion with proteinase K, high salt extraction of proteins, and ethanol precipitation. Southern analyses were performed to genotype the mice and to determine clonality of the lymphomas. DNA was digested with BamHI for genotyping or with HindIII for the clonality analysis, electrophoresed on 1% agarose gels (FMC Rockland, ME), vacuum blotted with 0.4 N NaOH onto nylon membranes (Gene Screen Plus, NEN Boston, MA), hybridized with DNA probes that had been radiolabeled with Klenow polymerase (New England Biolabs, Beverly, MA), washed, and subjected to autoradiography. Probes used for genotyping were a 1.2 kb EcoRI fragment comprising the entire p53 cDNA (Johnson et al., 1991) and a 1.1 kb BamHI fragment comprising the entire mouse CKIIa cDNA (Seldin and Leder, 1995) . A 1.8 kb DNA probe for the J b 2B exon of the T cell receptor was used to determine the clonal nature of the lymphomas (Siu et al., 1984) .
Polymerase chain reaction (PCR) of genomic DNA was also employed for genotyping. To detect the CK2a transgene, a sense oligonucleotide primer from the mouse CK2a cDNA coding sequence (5'-GGGATTTCTTCAGTGCCATC-3') and an antisense oligonucleotide from the SV40 polyA tail of the vector construct (5'-CCCATTCATAAGTTCCATAG-3') were employed. PCR was performed in an MJ Research thermal cycler (Watertown, MA) by denaturing at 948C for 30 s, annealing at 528C for 1 min and extending at 728C for 1 min for a total of 30 cycles. PCR primers were designed to distinguish the wild type and null p53 alleles: a sense oligonucleotide from the fourth intron of the murine p53 gene (5'-ATTCTCTGCATCTCTCCAGGGGAC-3') and an antisense oligonucleotide from the ®fth exon (5'-CATCAC-CATCGGAGCAGCGCTCATG-3') ampli®ed a 760 bp fragment for the wild type allele. The same sense oligonucleotide and an antisense oligonucleotide from the POL II sequence of the`knock-out' construct (5'-TTTACGGAGCCCTGGTC-GATG-3') ampli®ed a 390 bp fragment for the null allele (Donehower et al., 1992) . PCR was performed by denaturing at 958C for 30 s, annealing at 608C for 1 min, extending at 728C for 1 min for a total of 30 cycles.
RNA was extracted from fresh tissues with CsCl (Chirgwin et al., 1979) or with Ultraspec RNA (Biotecx Laboratories Inc., Houston, TX). Northern analysis of total RNA was performed using probes for murine myc (Stewart et al., 1984) , Tal-1 (Kelliher et al., 1996) , Hox-11 and Lmo-2. The probes for Hox-11 and Lmo-2 were generated by gel puri®cation of PCR-ampli®ed fragments (Lowsky et al., 1997) . For detection of Lmo-2 expression by PCR, lymphoma RNA was digested with DNAse I (Boehringer Mannheim, Indianapolis, IN) for 45 min at 378C, ®rst strand cDNA was synthesized by reverse transcription using 5 ± 10 mg of RNA (Stratagene, La Jolla, CA), and PCR was performed to obtain a 470 bp product (Lowsky et al., 1997) . As a control for mRNA quality and ®rst strand synthesis, hprt was ampli®ed with the sense oligonucleotide (5'-GTTGGATACAGGCCAGACTTTGTTG-3') and the antisense oligonucleotide (5'-GAGGG-TAGGCTGGCCTATAGGCT-3') to yield a 352 bp product (Johnson et al., 1988) .
